The importance of reducing cardiovascular risk in patients with type 2 diabetes
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information
PC-GB-104395 April 2021